1. Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis
- Author
-
Ozan Cemal Icacan, Ahmet Omma, Özlem Pehlivan, Sinem Girgin, Nilufer Alpay-Kanitez, Sevinç Can-Sandikçi, Selda Çelik, Cemal Bes, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Pehlivan, Özlem, Omma, Ahmet, Can-Sandıkçı, Sevinç, Girgin, Sinem, İçaçan, Ozan Cemal, Çelik, Selda, Bes Cemal, and School of Medicine
- Subjects
Male ,rheumatoid arthritis ,safety ,medicine.medical_specialty ,Arthritis ,Observational Study ,elderly ,Medication Adherence ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Sulfasalazine ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Leflunomide ,Aged ,Retrospective Studies ,business.industry ,Conventional disease ,Modifying antirheumatic drugs ,Elderly ,Retention rates ,Rheumatoid arthritis ,Safety ,Case-control study ,Age Factors ,Hydroxychloroquine ,Medication adherence ,Age factors ,Antirheumatic agents ,General Medicine ,Middle Aged ,medicine.disease ,Rheumatology ,retention rates ,030220 oncology & carcinogenesis ,Antirheumatic Agents ,Case-Control Studies ,Female ,Patient Safety ,business ,medicine.drug ,Research Article ,conventional disease-modifying antirheumatic drugs - Abstract
Physicians are challenged by the recognition and treatment of older patients with rheumatoid arthritis (RA). The aim of this case-control study was to evaluate the retention and safety of conventional disease-modifying anti-rheumatic drugs in older patients with RA.In this observational case-control study, we assessed older patients with RA (≥65 years) who were diagnosed in 3 different rheumatology centers from Turkey. Patients were divided as to those aged ≥65 years (elderly rheumatoid arthritis [ERA]) and those aged, NA
- Published
- 2020